Provider review
Paid partnerHumeCare+ sells compounded semaglutide and tirzepatide inside a program built around body-composition tracking, and it publishes a real provider directory and a clear state list. It puts no price on its homepage, prices only one of its two compounds, and its own pages disagree about its guarantee and about who leads its medical team.
Disclosure score, 6 checks
Best fora reader who wants compounded semaglutide with body-composition tracking and will confirm the charge and the guarantee terms at checkout
HumeCare+ also sells 1 compound this site boards without publishing a price for it: Tirzepatide.
What HumeCare+ states on its own site about leaving, getting money back, and what delivery costs. Read on September 2026.
Whether HumeCare+ charges to belong, on top of what it charges for the medication. Read on September 2026.
Whether HumeCare+ identifies the clinician or medical practice behind the prescription, or describes them only as a group. Read on September 2026.
HumeCare+ is a paid partner; this link may earn a commission. Full disclosure.
The homepage prints no figure at all. Every call to action on it leads to an eligibility quiz, and the first screens of that quiz ask about your goals and your sex at birth without showing a plan.
The figure is on a microdose landing page that the site lists in its sitemap and no other page links to. It is billed monthly, and the page says it covers medication if prescribed, ongoing care and the app.
The same page's FAQ calls that figure a starting point for the first four weeks. The terms also reserve extra charges for certain medications, doses and formulations, to be disclosed at fulfillment.
Other landing pages print an introductory monthly offer, a per-day figure, or an unfilled placeholder where the price should be. A whole family of them prints its introductory offer in British pounds. Treat every one of them as a floor and confirm the charge at checkout.
The microdose page names two medications, compounded semaglutide and compounded tirzepatide, under a single program figure.
The disclosure that carries the figure goes on to describe compounded semaglutide. Nothing on the page puts a figure beside tirzepatide, so its cost is the first question to ask if that is the drug you want.
The homepage never says which drug it prescribes. It speaks of personalized GLP-1 medication, and the two drugs are offered by name only on landing pages and in the safety information.
The terms also describe a route for FDA-approved brand-name GLP-1s, but no page offers or prices one.
HumeCare+ publishes a licensed provider directory. It names its clinical network, MDI Medical Group PC, and lists each prescriber with a license number for Massachusetts, Rhode Island and Vermont.
That lets you check a license before a visit, which a promise of licensed clinicians never does.
The marketing pages tell a different story. The homepage names one chief medical officer and a specialist prescriber, and the microdose page names a different chief medical officer.
None of those three names appears in the directory, and the terms say the company does not employ physicians. Judge the clinical side by the directory, not by the marketing pages.
The homepage promises your money back if you do not lose ten percent of your body weight in six months. Landing pages advertise a 180-day promise, and some of them list a 90-day money-back guarantee further down the same page.
The terms contain only the 90-day version. It pays out when you show no measurable weight loss at all, not when you miss a target.
It applies only to first-time GLP-1 users who, among other conditions, log every dose and all thirteen weekly weigh-ins on the company's smart scale. The consultation fee is excluded either way.
Outside that guarantee, the terms refund the membership only when a clinician finds you ineligible. Every other fee is non-refundable.
A dedicated coverage page lists the states served and names four it does not serve: Alabama, Arkansas, Louisiana and Mississippi. The microdose page leaves Arkansas off that list, so go by the coverage page.
No pharmacy is named. The terms say compounded prescriptions are filled by licensed compounding pharmacies and that you will be offered a choice of pharmacy partners, without naming one.
You can cancel from the account section of the web app or by email, at least 48 hours before renewal. There is no refund for a partly used period.
No page describes lab work as part of what you pay.
CareBareRX names four pharmacies, its physicians with NPI numbers and the company behind the brand, then prints its NAD+ and GLP-1 prices everywhere except its own product pages.
Read the full CareBareRX review
CareBareRX is a paid partner; this link may earn a commission. Full disclosure.
Visit CareBareRXYes, but not on its homepage. A microdose landing page prints a monthly figure, billed monthly, that it says includes the medication if prescribed. Its own FAQ calls that a starting figure.
Compounded semaglutide and compounded tirzepatide, both named on its landing pages and in its safety information. Only semaglutide has a figure beside it.
Yes. A public directory names its clinical network, MDI Medical Group PC, and lists prescribers with license numbers for three states. The chief medical officers named on its marketing pages are not in it.
The terms offer a 90-day guarantee to first-time GLP-1 users who log every dose and weekly weigh-in and still lose nothing measurable. The homepage's ten-percent promise does not appear in the terms.
Its coverage page lists every state except Alabama, Arkansas, Louisiana and Mississippi, and includes Washington, D.C.
No. The terms refer to licensed compounding pharmacies and pharmacy partners without naming one.
HumeCare+ is a paid partner; this link may earn a commission. Full disclosure.